Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457060 | 0.82 | DAO (0.70) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL2327781 | 0.82 | DAO (0.70) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL3173051 | 0.82 | DAO (0.70) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL6630374 | 0.78 | DAO (0.64) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL30147642 | 0.78 | DAO (0.64) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL24198807 | 0.78 | DAO (0.64) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL1243954 | 0.78 | DAO (0.64) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL4146436 | 0.76 | DAO (0.61) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL14434543 | 0.75 | DAO (0.60) | DAOHRH4TSHRKDM4EHSD17B10 | |
| SCHEMBL1161150 | 0.74 | DAO (0.58) | DAOHRH4TSHRKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | claimed |
| CN-102614514-B | GLP-1 acceptor agonists used for treating pains | WANG YONGXIANG | 2014-12-10 | — | — | CN | claimed |
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| WO-2012100748-A1 | GLP-1 RECEPTOR AGONIST FOR TREATING PAIN | WANG YONGXIANG (CN) | 2012-08-02 | — | — | WO | claimed |
| US-20090306169-A1 | Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors | BRANDISH PHILIP E | 2009-12-10 | — | — | US | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
| EP-1088824-B1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER INC. | 2003-10-16 | — | — | US | claimed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | claimed |
| US-6399601-B1 | ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-06-04 | — | — | US | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-4381284-B1 | LIGAND-TARGET INTERACTION ANALYSIS BY PHOTOCHEMICALLY INDUCED DYNAMIC NUCLEAR POLARIZATION (PHOTO-CIDNP) ENHANCED NMR SPECTROSCOPY | ETH ZUERICH (CH) | 2025-07-09 | — | — | EP | disclosed |
| EP-4577551-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-1157695-A1 | Method of treating obesity using a neurotensin receptor ligand | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125580-A2 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306169-A1 | Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors | DAO, DDO, MAOB | DAO 1/4885HRH4 1609/4885TSHR 4179/4885 |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, GYS1, PYGM | DAO 1915/4885HRH4 3088/4885TSHR 3091/4885 |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | DAO 286/4885HRH4 3677/4885TSHR 4084/4885 |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | DAO 1906/4885HRH4 3448/4885TSHR 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.